{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:28Z","timestamp":1791903508789,"version":"4.3.4"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011634","name":"Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.addr.2020.04.002","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T20:09:13Z","timestamp":1586808553000},"page":"364-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes"],"prefix":"10.1016","volume":"159","author":[{"given":"Nuphar","family":"Veiga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Diesendruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2020.04.002_bb0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3389\/fgene.2018.00695","article-title":"Crosstalk of genetic variants, allele-specific DNA methylation, and environmental factors for complex disease risk","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0015","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s12325-018-0795-9","article-title":"Emerging therapies for inflammatory bowel disease","volume":"35","author":"Weisshof","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/gim.2015.70","article-title":"Age-related macular degeneration: genome-wide association studies to translation","volume":"18","author":"Black","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/0269881116653109","article-title":"Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia","volume":"30","author":"de Jong","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.addr.2020.04.002_bb0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrg2344","article-title":"Genome-wide association studies for complex traits: consensus, uncertainty and challenges","volume":"9","author":"McCarthy","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fcvm.2018.00056","article-title":"Translating GWAS findings to novel therapeutic targets for coronary artery disease","volume":"5","author":"Shu","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0040","first-page":"3974","article-title":"In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease","volume":"27","author":"Uenaka","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","article-title":"10 years of GWAS discovery: biology, function, and translation","volume":"101","author":"Visscher","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0050","series-title":"AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science","first-page":"237","article-title":"Learning opportunities for drug repositioning via GWAS and PheWAS findings","volume":"2017","author":"Yin","year":"2018"},{"key":"10.1016\/j.addr.2020.04.002_bb0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng.2915","article-title":"Loss-of-function mutations in SLC30A8 protect against type 2 diabetes","volume":"46","author":"Flannick","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0060","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/acs.bioconjchem.5b00607","article-title":"Transforming nanomedicines from lab scale production to novel clinical modality","volume":"27","author":"Landesman-Milo","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2020.04.002_bb0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2016.07.052","article-title":"Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines","volume":"244","author":"Hazan-Halevy","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0075","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current Progress in non-viral RNAi-based delivery strategies to lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2017.00069","article-title":"Advanced strategies in immune modulation of cancer using lipid-based nanoparticles","volume":"8","author":"Mizrahy","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2020.04.002_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neuroscience.2015.06.038","article-title":"TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects","volume":"302","author":"Probert","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.addr.2020.04.002_bb0090","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.smim.2017.08.015","article-title":"Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-an innate immune system standpoint","volume":"34","author":"Granot","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2020.04.002_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2052-8426-2-5","article-title":"Harnessing RNAi nanomedicine for precision therapy","volume":"2","author":"Peer","year":"2014","journal-title":"Mol. Cell. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.copbio.2015.12.011","article-title":"RNA nanomedicines: the next generation drugs?","volume":"39","author":"Singh","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0105","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","article-title":"Introduction to current and future protein therapeutics: a protein engineering perspective","volume":"317","author":"Carter","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"2001","key":"10.1016\/j.addr.2020.04.002_bb0110","first-page":"7625","article-title":"The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10","volume":"166","author":"Lindsay","year":"1950","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2020.04.002_bb0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1472-6750-14-73","article-title":"Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis","volume":"14","author":"Zurita-Turk","year":"2014","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1530","article-title":"Nanoscale platforms for messenger RNA delivery, Wiley interdisciplinary reviews","volume":"11","author":"Li","year":"2019","journal-title":"Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0130","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.addr.2012.08.014","article-title":"RNAi-based nanomedicines for targeted personalized therapy","volume":"64","author":"Daka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.04.002_bb0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2013.07.029","article-title":"Omics-based nanomedicine: the future of personalized oncology","volume":"352","author":"Rosenblum","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2020.04.002_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.04.002_bb0145","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.04.002_bb0150","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0155","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4161\/rna.20206","article-title":"RNA mediated toll-like receptor stimulation in health and disease","volume":"9","author":"Dalpke","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.addr.2020.04.002_bb0160","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-11-0859","article-title":"Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c","volume":"17","author":"Saad","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2020.04.002_bb0165","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.addr.2020.04.002_bb0170","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2020.04.002_bb0175","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41598-017-06381-y","article-title":"Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.04.002_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2020.04.002_bb0185","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Current Gene Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy, molecular therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Meth. Clin. Devel."},{"key":"10.1016\/j.addr.2020.04.002_bb0195","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.addr.2020.04.002_bb0200","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics, molecular therapy","volume":"6","author":"Huang","year":"2017","journal-title":"Nucleic Acids"},{"key":"10.1016\/j.addr.2020.04.002_bb0210","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.04.002_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061302","article-title":"A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey","volume":"23","author":"Oberemok","year":"2018","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.addr.2020.04.002_bb0220","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1042\/BCJ20160759","article-title":"Molecular mechanisms of dicer: endonuclease and enzymatic activity","volume":"474","author":"Song","year":"2017","journal-title":"The Biochem. J."},{"key":"10.1016\/j.addr.2020.04.002_bb0225","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.04.002_bb0230","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.febslet.2005.08.079","article-title":"Dicing and slicing: the core machinery of the RNA interference pathway","volume":"579","author":"Hammond","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2020.04.002_bb0235","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.04.002_bb0240","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.04.002_bb0245","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0250","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","article-title":"Messenger RNA therapy for rare genetic metabolic diseases","volume":"68","author":"Berraondo","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.addr.2020.04.002_bb0255","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nantod.2018.10.005","article-title":"mRNA therapeutics deliver a hopeful message","volume":"23","author":"Zhong","year":"2018","journal-title":"NanoToday"},{"key":"10.1016\/j.addr.2020.04.002_bb0265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2020.04.002_bb0275","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA Therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.1016\/j.addr.2020.04.002_bb0280","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.04.002_bb0285","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0290","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0295","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0300","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0305","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.addr.2020.04.002_bb0310","unstructured":"M.H. Porteus, D. Carroll, Gene targeting using zinc finger nucleases."},{"key":"10.1016\/j.addr.2020.04.002_bb0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.copbio.2014.11.010","article-title":"Plant genome editing by novel tools: TALEN and other sequence specific nucleases","volume":"32","author":"Sprink","year":"2015","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0320","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3843","article-title":"Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene","volume":"35","author":"Chen","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0325","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2020.04.002_bb0330","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2020.04.002_bb0335","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.addr.2020.04.002_bb0340","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nature Biomed. Eng."},{"key":"10.1016\/j.addr.2020.04.002_bb0345","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.addr.2020.04.002_bb0350","doi-asserted-by":"crossref","first-page":"119302","DOI":"10.1016\/j.biomaterials.2019.119302","article-title":"In situ repurposing of dendritic cells with CRISPR\/Cas9-based nanomedicine to induce transplant tolerance","volume":"217","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.04.002_bb0355","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant Adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annual Rev. Virol."},{"key":"10.1016\/j.addr.2020.04.002_bb0360","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2020.04.002_bb0365","series-title":"Gene and Cell Therapy: Biology and Applications","first-page":"111","article-title":"Viral- and non-viral-based hybrid vectors for gene therapy","author":"Mahato","year":"2018"},{"key":"10.1016\/j.addr.2020.04.002_bb0370","article-title":"siRNA delivery strategies: a comprehensive review of recent developments","volume":"7","author":"Tatiparti","year":"2017","journal-title":"Nanomaterials (Basel, Switzerland)"},{"key":"10.1016\/j.addr.2020.04.002_bb0375","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/gt.2017.6","article-title":"Genetic pharmacology: progresses in siRNA delivery and therapeutic applications","volume":"24","author":"Scherman","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0380","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","article-title":"Action and reaction: the biological response to siRNA and its delivery vehicles","volume":"20","author":"Kanasty","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0385","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1039\/C7CS00479F","article-title":"Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics","volume":"47","author":"Shen","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2020.04.002_bb0390","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0395","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett."},{"issue":"2015","key":"10.1016\/j.addr.2020.04.002_bb0400","first-page":"5446","article-title":"A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA","volume":"194","author":"Mehta","year":"1950","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2020.04.002_bb0405","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/anie.200604295","article-title":"siRNA delivery into human T cells and primary cells with carbon-nanotube transporters","volume":"46","author":"Liu","year":"2007","journal-title":"Angew. Chem."},{"key":"10.1016\/j.addr.2020.04.002_bb0410","doi-asserted-by":"crossref","first-page":"28709","DOI":"10.1038\/srep28709","article-title":"Efficient nucleic acid delivery to murine regulatory T cells by gold nanoparticle conjugates","volume":"6","author":"Gamrad","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2020.04.002_bb0415","first-page":"12","article-title":"Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment","author":"Titov","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2020.04.002_bb0420","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.addr.2020.04.002_bb0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.04.002_bb0430","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00109-004-0558-8","article-title":"Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection","volume":"82","author":"Dass","year":"2004","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.addr.2020.04.002_bb0435","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1126\/science.1149859","article-title":"Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target","volume":"319","author":"Peer","year":"2008","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.addr.2020.04.002_bb0440","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","article-title":"Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure","volume":"84","author":"Felgner","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0445","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0450","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.04.002_bb0455","doi-asserted-by":"crossref","first-page":"12573","DOI":"10.1021\/bi00208a007","article-title":"Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids","volume":"33","author":"Bailey","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2020.04.002_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2020.04.002_bb0465","doi-asserted-by":"crossref","first-page":"12881","DOI":"10.1073\/pnas.1306529110","article-title":"Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery","volume":"110","author":"Alabi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0470","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/nn506248s","article-title":"Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles","volume":"9","author":"Cohen","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.04.002_bb0475","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1021\/acsnano.7b04734","article-title":"Next-generation lipids in RNA interference therapeutics","volume":"11","author":"Rietwyk","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.04.002_bb0480","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1073\/pnas.1519273113","article-title":"Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies","volume":"113","author":"Weinstein","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0485","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1021\/ja301621z","article-title":"Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation","volume":"134","author":"Chen","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2020.04.002_bb0490","article-title":"Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0495","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2020.04.002_bb0500","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Therapeutics"},{"key":"10.1016\/j.addr.2020.04.002_bb0505","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/IJN.S106625","article-title":"Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside","volume":"11","author":"Zatsepin","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2020.04.002_bb0510","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.04.002_bb0515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/B978-0-12-800148-6.00002-X","article-title":"Lipid nanoparticles for gene delivery","volume":"88","author":"Zhao","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.addr.2020.04.002_bb0520","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.addr.2020.04.002_bb0525","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1039\/C4IB00150H","article-title":"Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery","volume":"6","author":"Chang","year":"2014","journal-title":"Integr. Biol."},{"key":"10.1016\/j.addr.2020.04.002_bb0530","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0535","doi-asserted-by":"crossref","first-page":"e1906128","DOI":"10.1002\/adma.201906128","article-title":"A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes","author":"Ramishetti","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2020.04.002_bb0540","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2011.06.031","article-title":"Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response","volume":"156","author":"Mizrahy","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0545","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0005-2736(03)00106-8","article-title":"Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes","volume":"1612","author":"Peer","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2020.04.002_bb0550","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0555","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.68","article-title":"Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of Sclerostin in vivo","volume":"5","author":"Basha","year":"2016","journal-title":"Molecular Therapy. Nucleic Acids"},{"key":"10.1016\/j.addr.2020.04.002_bb0565","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/mt.2011.190","article-title":"Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells","volume":"19","author":"Basha","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0570","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2018.01.016","article-title":"Terminology matters: there is no targeting, but retention","volume":"273","author":"Reineke","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0585","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0590","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.04.002_bb0595","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/mt.2015.175","article-title":"Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses","volume":"24","author":"Katakowski","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0600","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1073\/pnas.0608491104","article-title":"Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1","volume":"104","author":"Peer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2020.04.002_bb0605","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0610","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/978-1-61779-166-6_29","article-title":"Integrin-targeted nanoparticles for siRNA delivery","volume":"757","author":"Ben-Arie","year":"2012","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.addr.2020.04.002_bb0615","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2010.11.002","article-title":"Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor","volume":"150","author":"Manjappa","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0620","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-5793(94)00313-0","article-title":"Biosynthetic lipid-tagging of antibodies","volume":"346","author":"Keinanen","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2020.04.002_bb0625","series-title":"Proceedings of the National Academy of Sciences of the United States of America","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017"},{"key":"10.1016\/j.addr.2020.04.002_bb0630","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","year":"2001","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.addr.2020.04.002_bb0635","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4155\/tde.12.10","article-title":"Novel methods and devices to enhance transdermal drug delivery: the importance of laser radiation in transdermal drug delivery","volume":"3","author":"Gomez","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2020.04.002_bb0640","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0645","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/1061186X.2016.1172587","article-title":"Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles","volume":"24","author":"Ramishetti","year":"2016","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2020.04.002_bb0650","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.addr.2018.12.002","article-title":"Engineering lymphocytes with RNAi","volume":"141","author":"Ramishetti","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2020.04.002_bb0655","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/smll.201502273","article-title":"Modulation of immune response using engineered nanoparticle surfaces","volume":"12","author":"Moyano","year":"2016","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.addr.2020.04.002_bb0660","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2019.05.032","article-title":"Therapeutic mRNA delivery to leukocytes","volume":"305","author":"Granot-Matok","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0665","first-page":"e1582","article-title":"Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation, Wiley interdisciplinary reviews","author":"Guo","year":"2019","journal-title":"Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2020.04.002_bb0670","first-page":"1173","article-title":"Marked stimulation of lymphocyte-mediated attack on tumor cells by target-directed liposomes containing immune RNA","volume":"38","author":"Magee","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2020.04.002_bb0675","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1749-6632.1978.tb22032.x","article-title":"Potentiation of interferon production and stimulation of lymphocytes by polyribonucleotides entrapped in liposomes","volume":"308","author":"Magee","year":"1978","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2020.04.002_bb0680","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000076464","article-title":"Evaluation of an mRNA lipofection procedure for human dendritic cells and induction of cytotoxic T lymphocytes against enhanced green fluorescence protein","volume":"24","author":"Okano","year":"2003","journal-title":"Tumour Biol."},{"key":"10.1016\/j.addr.2020.04.002_bb0685","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.gt.3301901","article-title":"Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes","volume":"10","author":"Grunebach","year":"2003","journal-title":"Gene Ther."},{"issue":"2002","key":"10.1016\/j.addr.2020.04.002_bb0690","first-page":"445","article-title":"Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection","volume":"25","author":"Lundqvist","year":"1997","journal-title":"J. Immunotherapy (Hagerstown Md.)"},{"key":"10.1016\/j.addr.2020.04.002_bb0695","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1021\/acsnano.8b00966","article-title":"Dendritic cell targeting mRNA Lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety","volume":"12","author":"Van der Jeught","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2020.04.002_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175784","article-title":"Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes","volume":"12","author":"Perri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2020.04.002_bb0705","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/SHK.0b013e318162cf17","article-title":"Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis","volume":"30","author":"Schwulst","year":"2008","journal-title":"Shock (Augusta, Ga.)"},{"key":"10.1016\/j.addr.2020.04.002_bb0710","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/art.24434","article-title":"Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis","volume":"60","author":"Andreakos","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.addr.2020.04.002_bb0715","doi-asserted-by":"crossref","first-page":"232001","DOI":"10.1088\/0957-4484\/21\/23\/232001","article-title":"RNAi nanomedicines: challenges and opportunities within the immune system","volume":"21","author":"Weinstein","year":"2010","journal-title":"Nanotechnology"},{"key":"10.1016\/j.addr.2020.04.002_bb0720","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2011.12.034","article-title":"Altering the immune response with lipid-based nanoparticles","volume":"161","author":"Landesman-Milo","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0725","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1093\/nar\/22.20.4307","article-title":"Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms","volume":"22","author":"Zelphati","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2020.04.002_bb0730","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood-2008-04-151191","article-title":"A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation","volume":"113","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.addr.2020.04.002_bb0735","doi-asserted-by":"crossref","first-page":"10249","DOI":"10.1016\/j.biomaterials.2013.09.019","article-title":"Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity","volume":"34","author":"Hajdu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2020.04.002_bb0740","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/mt.2009.271","article-title":"RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice","volume":"18","author":"Kim","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2020.04.002_bb0745","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2020.04.002_bb0750","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2019.10.001","article-title":"Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target","volume":"313","author":"Veiga","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2020.04.002_bb0755","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00262-012-1334-1","article-title":"Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2020.04.002_bb0760","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2020.04.002_bb0765","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.vaccine.2009.01.048","article-title":"Activation of toll-like receptor signaling pathway for protection against influenza virus infection","volume":"27","author":"Wong","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2020.04.002_bb0770","series-title":"Phase Ib\/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma","year":"2018"},{"key":"10.1016\/j.addr.2020.04.002_bb0775","series-title":"A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection","author":"Mirna Therapeutics","year":"2013"},{"key":"10.1016\/j.addr.2020.04.002_bb0780","series-title":"Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA)","year":"2019"},{"key":"10.1016\/j.addr.2020.04.002_bb0785","series-title":"EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors","year":"2019"},{"key":"10.1016\/j.addr.2020.04.002_bb0790","series-title":"First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)","year":"2018"},{"key":"10.1016\/j.addr.2020.04.002_bb0795","series-title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)","author":"GmbH","year":"2015"},{"key":"10.1016\/j.addr.2020.04.002_bb0800","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","article-title":"Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides","volume":"16","author":"Moss","year":"2019","journal-title":"Mol. Pharm."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20300223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X20300223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:55:35Z","timestamp":1759208135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X20300223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":160,"alternative-id":["S0169409X20300223"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2020.04.002","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2020.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}